Injective CEO says US INJ ETFs could launch before 2027
By Tobi Opeyemi Amure
AI summary of the source article
Injective co-founder and CEO Eric Chen projected that US exchange-traded funds linked to the INJ token could launch before 2027, speaking at Korea Blockchain Week. Currently, two applications are before the US Securities and Exchange Commission: the 21Shares Injective ETF and the Canary Staked INJ ETF, both of which submitted amended S-1 statements in September. Alongside ETF pursuits, Injective is targeting institutional adoption. Injective Institutional Services registered as an SEC transfer agent for tokenized securities in August, and the network launched its Meridian upgrade for institutional onchain tokenization. In Europe, Injective finalized its MiCA white paper and appears in the European Securities and Markets Authority's interim register.
Why it matters
The potential approval of INJ ETFs and Injective's registration as an SEC transfer agent illustrate growing institutional infrastructure and regulatory access for alternative crypto assets.
Key facts
- Two INJ ETF applications are currently before the SEC: 21Shares Injective ETF and Canary Staked INJ ETF.
- Injective Institutional Services registered with the SEC as a transfer agent for tokenized securities in August.
- Injective finalized its MiCA white paper in Europe, and INJ is listed on the European Securities and Markets Authority's interim register.